Physician profile
Devon M Carson
NPI 1831521087
$4,580.56
in general payments reported to CMS, 2019-2025
23 companies · $652 in 2025
The $652 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $619 · 2022: $726 · 2023: $895 · 2024: $1,689 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,210 · Education: $25.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.98 |
| Education | $25.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $604.26 | 2021-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $590.87 | 2021-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $533.41 | 2021-2025 | |
| Travere Therapeutics, INC. | $525.88 | 2023-2025 | Thiola |
| Akebia Therapeutics INC | $376.24 | 2021-2024 | Auryxia, Vafseo |
| Amgen INC. | $335.00 | 2024-2025 | Krystexxa |
| Novo Nordisk INC | $280.16 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.50 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $195.91 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $125.70 | 2021-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $122.42 | 2022-2024 | Velphoro, Korsuva |
| Ardelyx, INC. | $118.57 | 2024 | Xphozah 30 Mg, Ibsrela |
| Ani Pharmaceuticals, INC. | $107.36 | 2023-2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $91.75 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $86.79 | 2022-2024 | Tarpeyo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $84.02 | 2021-2024 | Rayaldee |
| Horizon Therapeutics Plc | $75.96 | 2022-2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $32.87 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.07 | 2024 | Terlivaz |
| Lundbeck LLC | $15.46 | 2021 | |
| Dexcom, INC. | $15.00 | 2021 | |
| Abbott Laboratories | $14.19 | 2023 | Freestyle Libre 3 |
| Amag Pharmaceuticals, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.